Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarMMa-3: bb2121 versus standard regimens in relapsed and refractory multiple myeloma
NL-OMON56296Phase 3Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jul 2020
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of idecabtagene vicleucel in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Started Jul 2020; status: recruiting.
02
Drugs
idecabtagene vicleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON56296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56296.